Nifedipine Medication Is Estimated To Witness High Growth Owing To Opportunity Of Treating Cardiovascular Diseases
Nifedipine medication is a calcium channel blocker used to treat hypertension and certain heart conditions such as angina. It works by relaxing and widening the blood vessels, which helps improve blood flow and lower blood pressure. Nifedipine also helps control and prevent chest pain from angina. With rising prevalence of cardiovascular diseases globally, nifedipine medication is widely prescribed for treating high blood pressure and cardiovascular conditions.
The global Nifedipine Medication Market is estimated to be valued at Us$ 1094.2 Mn in 2023 and is expected to exhibit a CAGR Of 8.5% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The growing prevalence of cardiovascular diseases presents a major market opportunity for nifedipine medication. According to WHO, cardiovascular diseases are the number one cause of death globally, taking an estimated 17.9 million lives each year. High blood pressure, also called hypertension, is a major risk factor that contributes to the prevalence of heart attacks and strokes worldwide. With rapidly aging populations in developed countries and increasing adoption of sedentary lifestyles in developing nations, the incidence of cardiovascular illnesses is expected to rise substantially in the coming years. This rising disease burden of cardiovascular diseases especially hypertension indicates a huge market potential for effective medications such as nifedipine in controlling and managing these conditions over the forecast period.
Porter’s Analysis
Threat of new entrants: The high capital requirement to enter the Nifedipine Medication Market poses a barrier for new companies. The presence of stringent regulations by regulatory bodies also acts as a deterrent for new players.
Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of substitute treatment options for patients. However, the criticality of cardiovascular diseases drives demand.
Bargaining power of suppliers: The presence of several raw material suppliers reduces their bargaining power. Suppliers face pressure on prices from manufacturers.
Threat of new substitutes: Alternatives like Amlodipine and Verapamil offer competition. However, the popularity and efficacy of Nifedipine keep the threat moderate.
Competitive rivalry: Major companies compete on the basis of generics, price, and new product/dosage launches.
SWOT Analysis
Strength: High efficacy in treating hypertensions and anginas. Wide acceptability among healthcare professionals.
Weakness: Patent expirations allowing generics erosion. Requirement of frequent dosing and monitoring.
Opportunity: Growing cardiovascular patient pool drives market potential. Product line extensions into new chronic conditions.
Threats: Pricing pressures from low-cost generics. Stringent regulatory norms for approvals.
Key Takeaways
The Global Nifedipine Medication Market Size is expected to witness high growth due to the rising prevalence of cardiovascular diseases worldwide.
Regional analysis:
North America dominates due to high healthcare spending and accessibility. Asia Pacific is the fastest growing region supported by growing medical tourism and healthcare reforms.
Key players:
Key players operating in the Nifedipine Medication Market are Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, GlaxoSmithKline plc, Lupin Limited, Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (a Novartis division), Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc. Major players compete through generics, new product launches and geographical expansion.
Get more insights on this topic :